N-myc/Alpha Satellite 2
Neuroblastoma is predominantly a tumor of early childhood. Hyperdiploid tumor DNA is associated with a favorable prognosis, especially in infants with neuroblastoma, while N-myc amplification is associated with a poor prognosis regardless of patient age. In contrast to N-myc gene amplification, the degree of expression of the N-myc gene in the tumor does not predict prognosis.

Amplification of the N-myc (MYCN) proto-oncogene occurs in 20% to 25% of neuroblastomas and is a reliable marker of aggressive clinical behavior. Consistent areas of chromosomal loss, including chromosome band 1p36 in 30% to 35% of primary tumors, 11q23 in 44%, and 14q23-qter in 22%, may identify the location of neuroblastoma suppressor genes.

The Qbiogene probe for N-myc uses the Universal Linkage System (ULS^®) and is optimized to detect amplification of the N-myc gene region. The included Chromosome 2 Alpha-Satellite probe serves as internal control and simultaneously defines the ploidy status of Chromosome 2.

This direct labeled probe has been tested and qualified on cultured cells, blood smears and are optimized for formalin-fixed paraffin-embedded tissue sections.

Technical Information:
The 2p24 N-myc(MYCN) specific DNA Probe is direct-labeled with Rhodamine (Exc max. 565 nm; Em. max. 590 nm). the Chromosome 2 Alpha-Satellite Probe is direct-labeled with Fluorescein (Exc. Max. 495 nm; Em max. 525 nm). The “RF” in the catalog number refers to patented repeat free “SET” technology used in this probe.

Localization:
Locus: 2p24.1
Gene: N-myc (MYCN)
Probe Size : 300 kb